LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

2.7 7.57

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.43

Max

2.76

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Aktsiakasum	-0.21
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-6.3M -42M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+330.28% upside

Turustatistika
By TradingEconomics
Turukapital	27M 574M
Eelmine avamishind	-4.87
Eelmine sulgemishind	2.7

Uudiste sentiment

By Acuity

75%

25%

351 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2025, 17:45 UTC

Tulu

Suurimad hinnamuutused turgudel

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. nov 2025, 17:31 UTC

Tulu

Suurimad hinnamuutused turgudel

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14. nov 2025, 16:15 UTC

Suurimad hinnamuutused turgudel

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14. nov 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. nov 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. nov 2025, 22:35 UTC

Tulu

Omandamised, ülevõtmised, äriostud

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. nov 2025, 22:32 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. nov 2025, 22:29 UTC

Tulu

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. nov 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. nov 2025, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

14. nov 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. nov 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. nov 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. nov 2025, 20:17 UTC

Omandamised, ülevõtmised, äriostud

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. nov 2025, 19:29 UTC

Market Talk

Tulu

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. nov 2025, 18:44 UTC

Market Talk

Tulu

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. nov 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. nov 2025, 17:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

14. nov 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

14. nov 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. nov 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. nov 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14. nov 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14. nov 2025, 16:30 UTC

Omandamised, ülevõtmised, äriostud

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14. nov 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14. nov 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14. nov 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. nov 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

330.28% tõus

12 kuu keskmine prognoos

Keskmine 10.8 USD 330.28%

Kõrge 15 USD

Madal 8 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

351 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.